Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Breast Cancer
Interventions: Tissue Expander (TE), Vancomycin and Gentamicin, Stimulan Rapid Cure; Procedure · Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Multiple Myeloma
Interventions: Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease
Interventions: Anti-inflammatory diet, Regular diet; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity
Interventions: mental contrasting with implementation intentions, telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!, Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All, Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Type 2
Interventions: Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin); Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 80
States / cities: Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Drug Addiction
Interventions: Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Menopause
Interventions: ACTH; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions: AZD5213 + pregabalin, Placebo, pregabalin capsules; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more

Conditions: Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions: extended-release exenatide; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 112
States / cities: Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more

Conditions: Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions: L-citrulline, Plasmalyte A; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Pelvic Organ Prolapse, Patient Preparedness
Interventions: Preoperative counseling office visit, Preoperative counseling phone call; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 99 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: IcoSema, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Concord, California • La Jolla, California + 37 more

Conditions: Chronic Migraine
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more

Conditions: Age-Related Osteoporosis
Interventions: Teriparatide, Alendronate; Drug
Lead sponsor: Madhumathi Rao; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lupus Erythematosus, Systemic
Interventions: Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator; Drug · Other
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more

Conditions: Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions: Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor; Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more

Conditions: Insulin Sensitivity, Obesity
Interventions: Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption; Other
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Back Pain, Chronic Low Back Pain, Internal Disc Disruption, Degenerative Disc Disease
Interventions: BIOSTAT BIOLOGX, Saline; Biological · Drug
Lead sponsor: Spinal Restoration, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 17 more

Conditions: Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions: LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride; Drug · Radiation
Lead sponsor: Ajjai Alva, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more

Conditions: Previously Treated Non Small Cell Lung Cancer
Interventions: AZD1775, AZD1775 Placebo, Antimitotic Agent, pegfiligrastim; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more

Conditions: Pancreatic Ductal Carcinoma
Interventions: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine; Other · Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more

Search by objective public record fields.

A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Sargramostim Use in COVID-19 to Recover Patient Health

Study of Dietary Composition in Crohn's Disease

WOOP VA: Promoting Weight Management in Primary Care

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Effects of MDMA on Social and Emotional Processing

Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Patient Preparedness for Pelvic Organ Prolapse Surgery

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma